^




Show legend
Group by Gene:
Include preclinical:

bevacizumab-maly
bevacizumab
bevacizumab-adcd
0
VEGF-A inhibitor
bevacizumab-awwb
Aybintio (bevacizumab biosimilar)
Krabeva (bevacizumab biosimilar)
bevacizumab-bvzr
nivolumab
PD1 inhibitor
1
PD1 inhibitor
pembrolizumab
dostarlimab
toripalimab
mTOR inhibitor
2
mTOR inhibitor
everolimus
temsirolimus
sirolimus
cabozantinib tablet
3
Multi-tyrosine kinase inhibitor
pazopanib
cabozantinib capsule
4
IFNα stimulant, VEGF-A inhibitor
bevacizumab + pegylated interferon α -2a
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
5
VEGFR inhibitor, PD1 inhibitor
pembrolizumab + axitinib
6
PD1 inhibitor, Multi-tyrosine kinase inhibitor
nivolumab + cabozantinib tablet
7
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
8
c-MET inhibitor
c-MET inhibitor
savolitinib
9
VEGFR inhibitor, PD-L1 inhibitor
avelumab + axitinib
10
HIF-2α inhibitor
belzutifan
11
VEGF-A inhibitor, EGFR inhibitor
bevacizumab + erlotinib
12
VEGFR inhibitor
VEGFR inhibitor
axitinib
13
EGFR inhibitor
erlotinib
14
ALK inhibitor
crizotinib
alectinib
PD-L1 inhibitor
15
PD-L1 inhibitor
atezolizumab
avelumab
16
CD70-targeted CAR-T immunotherapy
ALLO-316
17
PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab + cabozantinib tablet
18
PARP inhibitor
olaparib
19
CDK4 inhibitor, CDK6 inhibitor
palbociclib
20
mTORC1 inhibitor, mTORC2 inhibitor
CB-228
21
HDAC inhibitor, Multi-tyrosine kinase inhibitor
pazopanib + CG-781
22
PD1 inhibitor, IDO1 inhibitor
pembrolizumab + INCB024360
nivolumab + BMS-986205
23
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
24
VEGF-A inhibitor, PI3Kγ inhibitor, Bcl2 inhibitor, Tubulin inhibitor
bevacizumab + albumin-bound paclitaxel + IPI-549
25
VEGFR-2 inhibitor, c-MET inhibitor
GSK1363089
26
VEGFR inhibitor, mTOR inhibitor
temsirolimus + axitinib
27
FGFR inhibitor
ABSK091
28
BRAF inhibitor
vemurafenib
29
HIF-2α antagonist
PT2385
30
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
31
Immunotherapy
Immunotherapy
32
Immunotherapy, Tyrosine kinase inhibitor
Immunotherapy + Tyrosine kinase inhibitor
33
VEGF inhibitor
VEGF inhibitor
34
VEGFR inhibitor, Immunotherapy
Immunotherapy + VEGFR inhibitor
35
Glutamate inhibitor
Glutamate inhibitor
36
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
37
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
lenvatinib
38
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib
39
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
pembrolizumab + lenvatinib
40
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
everolimus + lenvatinib
41
CD122 agonist, IL-2 stimulant
aldesleukin
42
VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
tivozanib
43
TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
CDX-014
44
PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
bevacizumab + atezolizumab + IPI-549
45
PD-L1 inhibitor, VEGF-A inhibitor
bevacizumab + atezolizumab
46
VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
sunitinib + pazopanib
47
Topoisomerase II inhibitor
doxorubicin hydrochloride
48
pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
sorafenib + sunitinib
49
TGM2 inhibitor
MD102
50
MEK2 inhibitor, MEK1 inhibitor
U0126
51
CYP17A1 inhibitor
abiraterone acetate
52
PRC2 inhibitor
MRTX2219
53
RAC1 inhibitor
NSC23766
54
UCHL1 inhibitor, Androgen receptor inhibitor
enzalutamide capsule + 6RK73
55
pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + 4-methylumbelliferone
56
ATR inhibitor
M6620
57
DNA synthesis inhibitor
cisplatin
No biomarker
MET amplification
MET mutation
MET fusion
MET expression
PD-L1 expression
PD-L1 overexpression
PD-L1 underexpression
PBRM1 mutation
PBRM1 deletion
PBRM1 negative
PBRM1 overexpression
PBRM1 underexpression
MTOR mutation
KDR rs2071559
MTOR overexpression
KDR expression
KDR C482R
MTOR Q2223K
KDR overexpression
FLT1 rs9554320
FLT1 expression
FLT1 overexpression
AXL-L
ARID1A mutation
ROBO3 mutation
AXL overexpression
AXL expression
PD-1 expression
ALK rearrangement
VHL mutation
TSC2 mutation
HMOX1-L
HMOX1 expression
TSC1 deletion
TSC1 mutation
TSC2 H1620R + TSC2 Y1650C
HGF-L
HGF expression
HGF-H
PD-1-H
VHL promoter methylation
VHL deletion
LRP1B mutation
MSI-H/dMMR
BRCA1 mutation
BRCA2 mutation
KIM1 expression
FLCN mutation
TFE3 translocation
HDAC2 expression
ERVE-4 expression
HAVCR2 expression
SPP1-L
CXCL8-L
IL6-L
IL18 expression
ANGPT2 expression
TIMP1 expression
CSF1 expression
VEGFA expression
CXCL9 expression
IL18BP expression
SYNE1 mutation
CDKN2A mutation
CEACAM1 overexpression
CXCL10 overexpression
CA9 expression
CD31 expression
GNAQ mutation
IKZF2-L
KDM5C mutation
PDGFRA expression
CD8 expression
HIF1A expression
ELTD1 expression
BAP1 negative
IL6R L
IL6ST-H
TFEB translocation
EWSR1-POU5F1 fusion
KMT2C mutation
LDH elevation
CTLA4 promoter hypomethylation
NANOGNB mutation
PARP1 underexpression + PBRM1 mutation
PTTG1 overexpression
TNFRSF9 elevation
PD-L1 expression + CD14 positive
LAG3 positive + CD4 positive
TNFRSF9 positive + CD8 positive
TNFRSF9 positive + CD4 positive
NF2 mutation
FH mutation
FOLH1 overexpression
KHDRBS1 overexpression
PECAM1 underexpression
CD3G overexpression
NCAM1 overexpression
CD4 underexpression
PBRM1 mutation + SETD2 mutation
TERT promoter mutation
BRAF mutation
miR-138 underexpression + miR-497 overexpression
SETD2 mutation + TP53 mutation
CXCL8 elevation
VEGFA-H
BAP1 mutation
TERT overexpression
KIM1 elevation
IL6-H
CXCL10-H
CDKN2A deletion
BAP1 deletion
FLCN deletion
VEGFA overexpression
IL6 elevation
SETD2 mutation
VEGFA elevation
Tregs-H
DDR
T-cell-inflamed GEP signature
IFNG gene signature overexpression
BONSAI high signature
PAI1-H
HLA-A*03
HAS3 expression
DAPK1 underexpression
miR-155 underexpression
SMARCA4 mutation
KDM6A mutation
CCNE1 amplification
CTBP1 deletion
ACRBP amplification
PLK1 overexpression
GNAS amplification
MCAM overexpression
LRP10 deletion
SULT1A3 amplification
TP53 expression
CXCL11-H
EPAS1 overexpression
DDX39B overexpression
FGFR1 overexpression
AXL overexpression + PD-L1 expression
TP53 mutation
UGT1A9 expression
CXCL13 elevation
TNFSF13B elevation
TMB-H
CD44 positive
CD44 expression
ADCYAP1 deletion
IL7 elevation
CXCL12-H
NT5E overexpression
CD70 expression
PTEN deletion
IL13RA2 overexpression
CXCR4 overexpression
TGM2 overexpression
PRCC-TFE3 fusion
MTA2 overexpression
PGF overexpression
VEGFC underexpression
PDGFA underexpression
LAG3 expression
FLT4 overexpression
CCL4 elevation
CD27 overexpression
VEGFD overexpression
AR-V7 positive
VEGFB overexpression
Chr del(9)(p21.3)